The covid 19 infection has created a major havoc situation for the parents as the cases of the delta variant have been significantly increasing amongst the kids. More than 7 million cases since the start of the pandemic have been reported in the USA. 

Pfizer’s Child-Sized Vaccine Clinical Trial Failed – Recent Updates

As per the reports, there is a tremendous rise in the covid 19 cases amongst the kids, which happens to be 164,000 average sever day cases at an increasing rate of 24 percent. 

Pfizer's Child-Sized Vaccine Clinical Trial Failed - Recent Updates 

The healthcare authorities in the United States have been taking major steps to curb the cases amongst the kids. 

During the month of November, the US Food and Drug Administration authorized the use of vaccines for the age group between 5-11 years of kids. For children, Pfizer and BioNTech have reduced the dose size of vaccines. For children between the age group of 5 to 11 years, the dose size is 10 micrograms. 

Also, for the age group between 12-15, the FDA already approved the emergency use of vaccination, and for adolescents above 12, the dose size is 30 micrograms.  

The US FDA also gave a green signal for the emergency use of booster shots for 16-17 years old teenagers due to the inefficiency of the initial doses of the vaccines. 

Now per the preliminary data and analysis available during the clinical trials for the vaccine dose revealed that the vaccine is not able to produce the expected immunity in young children. 

The vaccine manufacturing company Pfizer announced through its statement on vaccines for younger children that the vaccine did not provide the desired results in terms of immunity and the company is planning to introduce a third dose of the same.

According to the company, the third vaccine dose of Pfizer and BioNTech vaccine is for children between six months to five years.  The independent analysis of both the child-sized vaccines confirmed that the vaccines are not producing the required immunity in children between six months and five years. And therefore, the company is thinking about introducing a third dose for the clinical trials. 

The company is working on developing a vaccine for the age group between 2-4 and has been conducting various trials stated by the CEO of Pfizer during a press meet. 

Dr. Anthony Fauci has been following every single minute development made by the vaccine companies to develop an effective and efficient vaccine without major long-term side effects. The changes in the vaccine dose for young children may cause a delay in introducing the vaccine. Dr. Anthony Fauci addressing this said, we must wait for another trial before authorizing the vaccine developers for the emergency use of vaccines on very young children. 

He also stated that after the complete analysis of the results and data, the vaccine dose is expected to be authorized by the first quarter of 2022.

Currently, there is no official confirmation about the vaccine authorization and introduction of a vaccine for younger children.